Show Notes
In this episode of This Could Save Your Life Podcast, hosts Dr Anna Mullins and Dr Catherine Bourke provide a comprehensive overview of cervical cancer screening and prevention. They start with the epidemiology of cervical cancer, outlining that it affects approximately 1 in 175 women or people with a cervix. Explaining the anatomy of the cervix and discussing the primary cause of cervical cancer: human papillomavirus (HPV) infection. They clarify that while HPV is very common and transmitted through sexual contact, most strains are cleared by the body and only a subset are associated with cancer development.
Covering common patient questions regarding HPV transmission, family history, and the relevance of these factors to individual risk. They emphasise that unlike many other cancers, a family history does not increase risk for cervical cancer.
Practical advice is presented around recognising possible symptoms of cervical cancer, such as abnormal vaginal bleeding, pelvic pain, and changes in vaginal discharge.
Exploring the details of cervical screening in Australia, which has shifted from Pap smears to HPV-based testing. Outlining the process and options for HPV testing, including both clinician-collected and self-collected swabs.
Screening start age (25) and end age (74) are clarified, as well as earlier screening for those sexually active before age 14, and the importance of starting screening upon sexual activity.
They also discussed cervical cancer prevention through vaccination. Referencing the development of the Gardasil vaccine in Australia, its almost 100% effectiveness against several HPV strains, and its routine administration to both girls and boys under the National Immunisation Program.
This Could Save Your Life Podcast is under The Good GP podcast, a proud member of the Talking HealthTech Podcast Network - the premier audio destination for cutting-edge insights and thought leadership in healthcare delivery, innovation, digital health, healthcare ICT, and commercialisation. Learn more at www.talkinghealthtech.com/podcast/network
More from The Good GP
In this episode of The Good GP, Dr Krystyna de Lange speaks with Dr Steph Daly, GP with a special interest in aged care and dementia, about the introduction of plasma biomarkers, specifically the p-Tau 217 blood test for Alzheimer’s disease. They explore what the p-Tau 217 test measures, its reliability, and its role in primary care.
In this episode of The Good GP, host Dr Krystyna De Lange speaks with Dr David Leitinger, a GP with a special interest in addiction medicine, about the practical use of naltrexone for managing alcohol use disorder (AUD).
In this episode of The Good GP, Dr Julia Rawlinson speaks with Dr Florence Martin, an epidemiologist specialising in pregnancy pharmacoepidemiology. Dr Martin discusses her recent study examining the relationship between first trimester antidepressant use and miscarriage risk, using UK primary care data from the CPRD GOLD database.
In this episode of the Good GP, Dr Julia Rawlinson speaks with Dr Julia Feutrill, consultant psychiatrist at King Edward Memorial Hospital and co-director of the Elizabeth Clinic. They discuss the complexities of antidepressant use during pregnancy, providing GPs with practical advice for navigating these conversations.
In this episode of the Good GP, Dr Julia Rawlinson speaks with Dr Paul Effler, Senior Medical Advisor at the WA Department of Health and expert in communicable diseases, about H5N1 avian influenza and pertussis.